RPTX Repare Therapeutics Inc.

26.35
+0.22  (+1%)
Previous Close 26.13
Open 25.78
52 Week Low 19.01
52 Week High 46.44
Market Cap $1,099,718,752
Shares 41,735,057
Float 26,233,366
Enterprise Value $829,429,039
Volume 74,024
Av. Daily Volume 271,882
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
RP-3500 - TRESR
Solid tumors
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
RP-3500 (ATTACC)
Solid Tumors
Phase 1/2
Phase 1/2
Phase 1b/2 dosing commenced August 2021.
RP-6306
Solid tumors
Phase 1
Phase 1
Phase 1 initiation of dosing announced May 3, 2021.

Latest News

  1. Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November. Details are as follows:

    Northland Synthetic Lethality Investor Conference
    Date: Wednesday, November 17, 2021
    Time: 9:30 a.m. Eastern Time

    Piper Sandler Healthcare Conference
    Date: Monday, November 29 – Thursday, December 2, 2021

    A live webcast of the Northland Synthetic Lethality Investor Conference panel discussions will be available starting Wednesday, November 17, 2021 at 9:30 a.m. Eastern…

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November. Details are as follows:

    Northland Synthetic Lethality Investor Conference

    Date: Wednesday, November 17, 2021

    Time: 9:30 a.m. Eastern Time

    Piper Sandler Healthcare Conference

    Date: Monday, November 29 – Thursday, December 2, 2021

    A live webcast of the Northland Synthetic Lethality Investor Conference panel discussions will be available starting Wednesday, November 17, 2021 at 9:30 a.m. Eastern Time in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company's website for 90 days.

    The prerecorded Piper Sandler Healthcare Conference fireside chat will be available on Monday, November 22, 2021 at 10 a.m. Eastern Time in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company's website for 90 days.

    About Repare Therapeutics, Inc.

    Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

    SNIPRx® is a registered trademark of Repare Therapeutics Inc.

    View Full Article Hide Full Article
  2. Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference

    Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations

    Gross Proceeds of $101.2 Million Raised in Upsized Follow-on Public Offering

    Thomas Civik appointed to Board of Directors as new Chairman

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.

    "We are pleased…

    Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference

    Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations

    Gross Proceeds of $101.2 Million Raised in Upsized Follow-on Public Offering

    Thomas Civik appointed to Board of Directors as new Chairman

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.

    "We are pleased with the progress we've made this quarter in our Phase 1 part of the RP-3500 program, including the comprehensive safety data and emerging evidence of activity from the TRESR study which was part of the featured oral presentation at the AACR-NCI-EORTC conference this year," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "The findings continue to suggest RP-3500 may have broad clinical efficacy in tumors with diverse genetic alterations and provides further clinical proof of concept and validation of our SNIPRx platform. We look forward to providing updates in the future on the potential of RP-3500, both as a monotherapy and in combination with PARP inhibitors."

    Third Quarter 2021 Review and Operational Updates:

    • Announced initial monotherapy clinical data from Phase 1/2 TRESR study of RP-3500 in patients with solid tumors at the AACR-NCI-EORTC conference
      • Early data showed RP-3500 appears safe and well tolerated. The most common treatment emergent adverse events in any of the 101 patients treated, expectedly, was grade 1-2 anemia, with only 21.8% of all patients experiencing Grade 3 anemia (no Grade 4). There were no discontinuations related to RP-3500 emergent adverse events and dose interruptions, and reductions or red blood cell transfusions were infrequent on the recommended 3 days on/4 days off weekly regimen.
      • Recommended Phase 2 dose and schedule for further monotherapy RP-3500 evaluation was determined to be 160mg, taken weekly for 3 days on and 4 days off. This schedule assures repeated weekly exposure to RP-3500 at an efficacious dose. The Grade 3 anemia rate at this schedule overall was only 14.5%.
      • Antitumor activity, defined as RECIST based objective responses, was observed in patients with tumors harboring SNIPRX predicted genomic alternations at doses >100mg (ATM, CDK12, BRCA1, BRCA2, RAD51C), across multiple tumor types and included patients after PARP inhibitor failure. Meaningful clinical benefit was observed in 49% of 69 patients with available scans. Those include 12 patients with tumor responses per established international efficacy criteria, 14 patients with ongoing stable disease for at least 16 weeks and an additional 8 patients with stable disease who only had two radiological evaluations, but had demonstrated significant decreases in tumor markers or initial tumor shrinkage of less than 30%. Promising deep molecular responses in circulating tumor DNA (ctDNA) for tumors with STEP2 genomic alterations were observed in a subset of patients available for serial ctDNA analysis.
      • Final readouts from patients enrolled in the monotherapy arm of the TRESR trial, as well as initial data from the combination arm testing RP-3500 together with PARP inhibitors, are expected in 2022.



    • Raised Gross Proceeds of $101.2 Million in Upsized Follow-on Public Offering
      • In November 2021, the Company announced the closing of an upsized unwritten follow-on public offering yielding aggregate gross proceeds of approximately $101.2 million, or net proceeds of approximately $93.9 million, after deducting underwriting commissions and estimated offering expenses of $1.2 million payable by us. All of the shares in the offering were offered by Repare Therapeutics.
    • Appointed Thomas Civik to Board of Directors as new Chairman
      • In September 2021, the Company appointed Thomas Civik to its Board of Directors as its Chairman. He replaced Jerel Davis, Ph.D., who remains a Board member.
      • Mr. Civik was most recently President and CEO of Five Prime Therapeutics until its $1.9 billion acquisition by Amgen in April 2021. He has over 25 years of leadership and commercial experience at various companies including Foundation Medicine and Genentech.
    • Achieved $0.9 million (¥100 million) research trigger pursuant to the terms of its research services, license and collaboration agreement with Ono Pharmaceutical Co., Ltd
      • On October 13, 2021, upon the occurrence of a specified research trigger, the Company became eligible to receive a portion, amounting to ¥100 million ($0.9 million), of the research service payments provided for in its research services, license and collaboration agreement with Ono Pharmaceutical Co., Ltd., or Ono, ("Ono Agreement") for the research of potential product candidates targeting Polθ. Furthermore, on October 29, the Company and Ono entered into an amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended by one year.

    Third Quarter 2021 Financial Results:

    • Cash and cash equivalents, restricted cash and marketable securities: Cash and cash equivalents, restricted cash and marketable securities as of September 30, 2021 were $268.2 million, exclusive of the proceeds from the follow-on public offering.
    • Research and development expenses, net of tax credits (Net R&D): Net R&D expenses were $25.4 million and $62.1 million for the three- and nine-month periods ended September 30, 2021, respectively, as compared to $10.1 million and $27.7 million for the three- and nine-month periods ended September 30, 2020, respectively. The increase in R&D expenses for the three and nine-month periods were primarily due to increases in development costs related to the Company's RP-3500 and RP-6306 programs, as well as increases in personnel related expenses, including share-based compensation.
    • General and administrative (G&A) expenses: G&A expenses were $6.6 million and $18.6 million for the three and nine-month periods ended September 30, 2021, respectively, as compared to $4.0 million and $9.6 million for the three and nine-month periods ended September 30, 2020, respectively. The increase in G&A expenses for the three and six-month periods were due to personnel related costs, including share-based compensation, and D&O insurance which increased as a result of the Company's IPO in June 2020.
    • Net loss: Net loss was $30.9 million, or $0.83 per share and $78.6 million, or $2.12 per share, in the three and nine-month periods ended September 30, 2021, respectively, and $13.8 million, or $0.37 per share and $38.2 million, or $2.63 per share in the three and nine-month periods ended September 30, 2020, respectively.

    About Repare Therapeutics' SNIPRx® Platform

    Repare's SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company's therapies based on the genetic profile of their tumors. Repare's platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

    About Repare Therapeutics, Inc.

    Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

    SNIPRx® is a registered trademark of Repare Therapeutics Inc.

    Forward-Looking Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical development of the Company's pipeline and its research and development programs, including the anticipated timing, anticipated patient enrollment, trial outcomes or associated costs of its clinical trials of RP-3500 and RP-6306; and the Company's ability to advance RP-6306, both as monotherapy and in combination with chemotherapies and other agents, into proof-of-concept trials in 2022. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company's business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed with the Securities and Exchange Commission ("SEC") and the Québec Autorité des Marchés Financiers ("AMF") on August 12, 2021, and its other documents subsequently filed with or furnished to the SEC and AMF. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

    Repare Therapeutics Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (Amounts in thousands of U.S. dollars, except share data)

     

     

     

    As of

    September 30,

     

     

    As of

    December 31,

     

     

     

    2021

     

     

    2020

     

    ASSETS

     

     

     

     

     

     

    CURRENT ASSETS:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    260,995

     

     

    $

    326,184

     

    Marketable securities

     

     

    7,194

     

     

     

    7,526

     

    Research and development tax credits receivable

     

     

    2,317

     

     

     

    2,011

     

    Other receivables

     

     

    767

     

     

     

    4,153

     

    Prepaid expenses

     

     

    9,103

     

     

     

    6,678

     

    Total current assets

     

     

    280,376

     

     

     

    346,552

     

    Property and equipment, net

     

     

    4,165

     

     

     

    3,948

     

    Restricted cash

     

     

     

     

     

    212

     

    Operating lease right-of-use assets

     

     

    7,253

     

     

     

    4,674

     

    Other assets

     

     

    1,008

     

     

     

    288

     

    Deferred tax assets

     

     

    2,843

     

     

     

    1,412

     

    TOTAL ASSETS

     

    $

    295,645

     

     

    $

    357,086

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

     

     

     

    CURRENT LIABILITIES:

     

     

     

     

     

     

    Accounts payable

     

    $

    1,860

     

     

    $

    2,251

     

    Accrued expenses and other current liabilities

     

     

    11,020

     

     

     

    5,975

     

    Operating lease liability, current portion

     

     

    1,458

     

     

     

    697

     

    Deferred revenue, current portion

     

     

    8,925

     

     

     

    2,073

     

    Income tax payable

     

     

    147

     

     

     

    18

     

    Total current liabilities

     

     

    23,410

     

     

     

    11,014

     

    Operating lease liability, net of current portion

     

     

    5,623

     

     

     

    3,308

     

    Deferred revenue, net of current portion

     

     

    48,359

     

     

     

    55,934

     

    TOTAL LIABILITIES

     

     

    77,392

     

     

     

    70,256

     

    SHAREHOLDERS' EQUITY

     

     

     

     

     

     

    Preferred shares, no par value per share; unlimited shares authorized

    as of September 30, 2021 and December 31, 2020, respectively; 0 shares issued

    and outstanding as of September 30, 2021, and December 31, 2020, respectively

     

     

     

     

     

     

    Common shares, no par value per share; unlimited shares authorized as of

    September 30, 2021 and December 31, 2020; 37,133,938 and 36,902,924 shares

    issued and outstanding as of September 30, 2021 and December 31, 2020, respectively

     

     

    385,990

     

     

     

    384,313

     

    Additional paid-in capital

     

     

    14,239

     

     

     

    5,875

     

    Accumulated deficit

     

     

    (181,976

    )

     

     

    (103,358

    )

    Total shareholders' equity

     

     

    218,253

     

     

     

    286,830

     

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

     

    $

    295,645

     

     

    $

    357,086

     

    Repare Therapeutics Inc.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (Unaudited)

    (Amounts in thousands of U.S. dollars, except share and per share data)

     

     

     

    Three Months Ended

    September 30,

     

     

    Nine Months Ended

    September 30,

     

     

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

     

    Revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Collaboration agreements

     

    $

    278

     

     

    $

     

     

    $

    723

     

     

    $

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development, net of tax credits

     

     

    25,361

     

     

     

    10,091

     

     

     

    62,075

     

     

     

    27,674

     

    General and administrative

     

     

    6,596

     

     

     

    3,996

     

     

     

    18,574

     

     

     

    9,551

     

    Total operating expenses

     

     

    31,957

     

     

     

    14,087

     

     

     

    80,649

     

     

     

    37,225

     

    Loss from operations

     

     

    (31,679

    )

     

     

    (14,087

    )

     

     

    (79,926

    )

     

     

    (37,225

    )

    Other income (expense), net

     

     

     

     

     

     

     

     

     

     

     

     

    Realized and unrealized gain (loss) on foreign exchange

     

     

    33

     

     

     

    290

     

     

     

    (92

    )

     

     

    (846

    )

    Interest income

     

     

    53

     

     

     

    156

     

     

     

    155

     

     

     

    156

     

    Other expense

     

     

    (7

    )

     

     

    (4

    )

     

     

    (21

    )

     

     

    (10

    )

    Total other income (expense), net

     

     

    79

     

     

     

    442

     

     

     

    42

     

     

     

    (700

    )

    Loss before income taxes

     

     

    (31,600

    )

     

     

    (13,645

    )

     

     

    (79,884

    )

     

     

    (37,925

    )

    Income tax recovery (expense)

     

     

    708

     

     

     

    (106

    )

     

     

    1,266

     

     

     

    (229

    )

    Net loss and comprehensive loss

     

    $

    (30,892

    )

     

    $

    (13,751

    )

     

    $

    (78,618

    )

     

    $

    (38,154

    )

    Net loss attributable to common shareholders—basic

    and diluted

     

    $

    (30,892

    )

     

    $

    (13,751

    )

     

    $

    (78,618

    )

     

    $

    (38,154

    )

    Net loss per share attributable to common

    shareholders—basic and diluted

     

    $

    (0.83

    )

     

    $

    (0.37

    )

     

    $

    (2.12

    )

     

    $

    (2.63

    )

    Weighted-average common shares outstanding—basic

    and diluted

     

     

    37,122,668

     

     

     

    36,756,694

     

     

     

    37,026,116

     

     

     

    14,486,896

     

     

    View Full Article Hide Full Article
  3. Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares. All common shares were sold by Repare. The total gross proceeds for the offering were approximately $101.2 million, before deducting underwriting commissions and offering expenses payable by Repare.

    Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler acted as joint…

    Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares. All common shares were sold by Repare. The total gross proceeds for the offering were approximately $101.2 million, before deducting underwriting commissions and offering expenses payable by Repare.

    Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler acted as joint book-running managers for the offering.

    The securities described above were offered pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on July 2, 2021. The offering was made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.

    Copies of the final prospectus supplement related to the offering and the accompanying prospectus may be obtained by visiting the SEC's website located at www.sec.gov or by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone: 1-866-471-2526 or by emailing ; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924 or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Repare Therapeutics, Inc.

    Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate, RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs.

    SNIPRx® is a registered trademark of Repare Therapeutics Inc.

    View Full Article Hide Full Article
  4. Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare. All of the common shares are being offered by Repare. The offering is expected to close on November 1, 2021, subject to customary closing conditions. In addition, Repare has granted the underwriters a 30-day option to purchase up to an additional 600,000 of its common shares at the…

    Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare. All of the common shares are being offered by Repare. The offering is expected to close on November 1, 2021, subject to customary closing conditions. In addition, Repare has granted the underwriters a 30-day option to purchase up to an additional 600,000 of its common shares at the public offering price, less underwriting commissions.

    Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler are acting as joint book-running managers for the offering.

    The securities described above are being offered pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on July 2, 2021. This offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.

    A preliminary prospectus supplement related to the offering (including the accompanying prospectus) has been previously filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement related to the offering and the accompanying prospectus may be obtained, when available, by visiting the SEC's website or by contacting:

    Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone: 1-866-471-2526 or by emailing ; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924 or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Repare Therapeutics, Inc.

    Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate, RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs.

    SNIPRx® is a registered trademark of Repare Therapeutics Inc.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Repare's expectations regarding the timing and completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the securities offering discussed above will be consummated on the terms described or at all. Completion of the offering is subject to numerous factors, many of which are beyond the control of Repare, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Repare's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings Repare makes with the SEC from time to time. Repare undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

    View Full Article Hide Full Article
  5. Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares. All common shares to be sold in the proposed offering will be sold by Repare. Repare also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares at the public offering price, less underwriting commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

    Morgan…

    Repare Therapeutics Inc. (NASDAQ:RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares. All common shares to be sold in the proposed offering will be sold by Repare. Repare also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares at the public offering price, less underwriting commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

    Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler are acting as joint book-running managers for the offering.

    The securities described above are being offered pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on July 2, 2021. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement. A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC's website located at www.sec.gov.

    When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may be obtained for free by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone: 1-866-471-2526 or by emailing ; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924 or by email at . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Repare Therapeutics, Inc.

    Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate, RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs.

    SNIPRx® is a registered trademark of Repare Therapeutics Inc.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Repare's expectations regarding the anticipated final terms, timing and completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Repare, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Repare's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings Repare makes with the SEC from time to time. Repare undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

    View Full Article Hide Full Article
View All Repare Therapeutics Inc. News